Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $25

Moomoo NewsAug 15 02:32 ET · Ratings

Express News | Astria Therapeutics Shares Are Trading Higher After the Company Reported Q2 Financial Results. Also, Oppenheimer Maintained an Outperform Rating on the Stock and Raised Its Price Target From $25 to $26

BenzingaAug 13 10:35 ET

A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35

Moomoo NewsAug 13 09:00 ET · Ratings

Express News | Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target

BenzingaAug 13 08:37 ET

Astria Therapeutics Is Maintained at Outperform by Oppenheimer

Dow JonesAug 13 08:29 ET

Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $26 From $25

ReutersAug 13 08:08 ET